BIO-Europe 2015 BIO EBD Group

Share/Follow Us

Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BIO-Europe® 2015 Press Releases

April 17, 2015Spotlight on Munich Business Facts Munich is home to a broad spectrum of high-capacity industries including life sciences; information and communication technology; automotive; aerospace; financial services; cross-industry technologies; skilled crafts; media/creative industries and corporate services. Munich is a growing city. The City of Munich has 1.46 million inhabitants (2013) and expects to grow to 1.65 ...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

June 12, 2015 Boehringer Ingelheim Pharmaceuticals: “The world is our laboratory” At Boehringer Ingelheim, “innovation is the element that defines us,” said Paola Casarosa, PhD, Corporate VP, Business Development and Licensing (BD&L)/Prescription Medicines. Its track record bears that out. Boehringer Ingelheim has a 125-year history of innovation that is based not only on its own discoveries but also upon novel finds from partners throughout the life sciences. more ►

June 11, 2015 Boston Children’s Hospital: Innovating from bench to bedside Translating innovation from the bench to the bedside is integral to the mission of Boston Children’s Hospital. Research runs the gamut from biotech and pharmaceutical development to devices, diagnostics and healthcare IT, and is led by researchers who often are appointed not just to Boston Children’s Hospital, but also to prestigious institutions in the area. more ►

June 3, 2015 Agilis builds value by tapping into Boston’s biotech ecosystem In November 2014, Gregory Robinson was named the Chief Scientific Officer for Agilis Biotherapeutics, a biotechnology company engineering best-in-class DNA therapeutics for patients afflicted with devastating rare diseases of the central nervous system (CNS). Formerly the Senior Director for Rare Diseases Business Development and the Head of Discovery Research at Shire, Robinson has stepped up to the challenge of advancing Agilis’ drug and therapy discovery programs. more ►

June 3, 2015 When de-risking, relationships matter De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata. “In the ‘old’ days, you’d look for others working with the same mechanism or against the same targets and hope their data lent confidence to your own investigations as you followed in their wake,” says Richard Brudnick senior VP, corporate development, Biogen, says. That approach reduced risk, but didn’t encourage great innovation. more ►

May 27, 2015 Atlas Venture: It takes a village Atlas Venture pioneered the “built-to-buy” business model a few years ago knowing that it takes a village to build a successful biotech company—assuming that village is populated by innovative scientists, serial biotech entrepreneurs, risk-tolerant investors and biopharma partners with the wherewithal to take drugs from clinical development to commercialization. more ►



Arrow Up


 
 

Follow this event: Follow us on Twitter
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD GmbH
Privacy Policy and Cookies
Terms of Use